Cholestyramine

Quick links to important sections

Cholestyramine

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cholestyramine

Property Description
Active ingredient Cholestyramine resin
Form Powder for oral suspension, Granules
Pharmacological class Bile acid sequestrant
Common use Reduction of high cholesterol levels
Origin Synthetic polymer

What Type of Medicine is Cholestyramine?

Cholestyramine is a synthetic, high-molecular-weight polymer classified pharmaceutically as a bile acid sequestrant, primarily used as a hypolipidemic agent. This means its fundamental role is to help reduce elevated levels of lipids, specifically cholesterol, in the bloodstream. Unlike many cholesterol-lowering medicines that work inside the body's cells or liver, Cholestyramine operates exclusively within the gastrointestinal tract, defining its unique non-systemic class of action. The primary mechanism of bile acid sequestrants involves working in the intestines to prevent bile acid reabsorption. It functions as an anion-exchange resin, a chemical description of the material that allows it to bind to other negatively charged compounds in the gut.


Composition and Preparation Form

The active ingredient of this medication is Cholestyramine resin, which is formulated as a single-entity product. Cholestyramine is most commonly supplied as a dry powder for oral suspension or in the form of granules. The original formulation was often marketed under the trade name Questran; however, it is now widely available as a generic. Because the resin itself is chemically inert and not absorbed by the body, it must be administered orally after being mixed thoroughly with water, juice, or another non-carbonated liquid, ensuring it is dispersed correctly before ingestion.


General Principle of Action and Benefit

The core mechanism of Cholestyramine is the binding to bile acids within the small intestine, preventing these substances from being re-absorbed back into the body's circulation. The drug promotes the fecal excretion of bile acids, a process that indirectly but effectively drives the medication's general benefit: the sustained reduction of circulating low-density lipoprotein (LDL) cholesterol levels, which is a key therapeutic goal for patients managing primary hypercholesterolemia.

What side effects are possible with Cholestyramine?

Possible Side Effects and Safety Information

Cholestyramine's safety profile, as documented in official regulatory sources, reflects its non-systemic mechanism of action, with adverse reactions largely concentrated in the gastrointestinal system. The most frequently reported effect is Constipation, which is classified as Very Common in official labeling. Other documented, less frequent gastrointestinal disturbances include abdominal discomfort, flatulence, nausea, vomiting, and diarrhea.


Documented Safety Constraints

The medicine's regulatory safety profile is structured by indirect metabolic consequences and specific population considerations. Due to its action in the intestine, prolonged use may lead to deficiencies of fat-soluble vitamins (A, D, E, K) and the risk of developing hyperchloremic acidosis. The label documents a rare but serious risk of intestinal obstruction, which has been noted in post-marketing reports, including in pediatric patients.

Special safety considerations are defined for certain patient groups. Older adults may experience an increased incidence of gastrointestinal complaints. The risk of hyperchloremic acidosis is heightened in pediatric patients and those with renal impairment.


Safety Restrictions

Cholestyramine is contraindicated in individuals with complete biliary obstruction because the medicine requires the presence of bile acids in the intestine to be effective. Caution is also advised in patients with pre-existing constipation, as the medicine can potentially worsen this condition.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Cholestyramine

Overdose Scope

The official overdose profile for Cholestyramine is defined by its non-systemic action. Regulatory documents state that the chief potential harm from an overdosage is the obstruction of the gastrointestinal tract. This is a physical risk resulting from the accumulation of the non-absorbed resin. Clinical signs associated with this risk may include severe stomach pain and severe constipation.

Emergency Actions and Management

When a suspected overdosage occurs, regulatory guidance mandates that patients seek emergency medical attention immediately or contact a poison control center. Immediate help is required if symptoms consistent with intestinal blockage, such as severe, persistent abdominal pain, are present.

Management of the overdose is procedural and is determined by the characteristics of the physical obstruction: specifically, the location of the obstruction, the degree of blockage, and the presence or absence of normal gut motility.

Special Considerations

Official labeling does not document a specific pharmacological antidote. Furthermore, rare reports of intestinal obstruction, including two fatalities, have been noted in pediatric patients, making this a critical population-specific consideration when overdosage is suspected.

Therapeutic Uses of Cholestyramine

What Cholestyramine Treats: Main Uses and Benefits

Cholestyramine is commonly used across domains where additional symptomatic support is needed, addressing several conditions. Its primary use involves supporting cardiovascular health by managing the asymptomatic biochemical elevation of LDL cholesterol (bad cholesterol). This supports maintaining functional stability by addressing a major cardiovascular risk factor.

It is also relevant in contexts marked by increased discomfort or tension from intense, chronic pruritus (itching). This distressing symptom cluster is specifically associated with the systemic imbalance of bile acids in cholestatic liver diseases or partial biliary obstruction. The medication contributes to improved comfort during periods of heightened symptoms by easing the overall symptom load. The medication is applied in addressing symptoms related to systemic imbalance, such as chronic bile acid-induced diarrhea.


The main conditions Cholestyramine is relevant for include primary hypercholesterolemia, pruritus associated with cholestasis, and bile acid-induced diarrhea. The therapeutic intent is the supportive management of systemic discomfort and a major cardiovascular risk factor.


Quick Fact: Relief for Intense Itching Cholestyramine is commonly used to help with symptoms related to inflammatory or irritative states, such as severe, chronic pruritus. It provides supportive relief when symptoms create noticeable physiological strain.

Regulatory References

  1. NIH StatPearls clinical overview

Eligibility and Restrictions for Use

Eligibility Scope

Cholestyramine is contraindicated and must not be used by patients with a complete biliary obstruction, as the drug requires bile to be present in the intestine to function. It is also contraindicated for individuals with a known hypersensitivity to the drug or its components.

Age-related eligibility specifies that use in children under 6 years of age is generally not established in official labeling, although pediatric use in older children is documented. Older adults (typically over 60) are noted to be more susceptible to constipation while taking this medicine, requiring careful dosage management.

Conditional Use applies to several populations. Patients with pre-existing constipation or hemorrhoids require caution, as the medicine may aggravate these conditions. Use in patients with renal impairment requires special consideration due to the risk of developing hyperchloremic acidosis with prolonged therapy. For individuals with Phenylketonuria (PKU), sugar-free formulations containing aspartame are restricted.

Pregnancy is classified as Category C (US FDA), indicating conditional use where the benefit must outweigh potential hazards, primarily due to the risk of the medicine interfering with fat-soluble vitamin absorption. Use during lactation is generally acceptable as the medicine is not systemically absorbed, but caution is still advised regarding maternal vitamin levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Findings
Medicinal product categories with documented interactions Acidic and neutral oral medications, Anticoagulants, Thyroid Hormones, Thiazide Diuretics, Fibrates, HMG-CoA reductase inhibitors, Fat-Soluble Vitamins, Folic Acid.
Specific interacting medicines (if explicitly listed) Warfarin, Levothyroxine, Digoxin, Hydrochlorothiazide, Fenofibrate, Ezetimibe, Tetracycline, Penicillin G, Phenylbutazone, Propranolol, Estrogens and Progestins, Nicotinic acid.
Mechanistic basis of interactions (only if stated in label) Non-Absorbable Pharmacokinetic Interference: Due to the physical binding property of the resin in the gastrointestinal tract, leading to reduced or delayed absorption of concomitant drugs.
Timing-based interaction rules (if applicable) All concomitant oral medication must be administered at least one hour before or 4 to 6 hours after Cholestyramine to minimize the potential for reduced absorption.

Interaction Classifications (High-Level)

Classification Official Regulatory Findings
Interaction severity classification (as defined in official documents) Use-with-Caution Combinations: Significant absorption interference requires mandatory timing separation. Additive Effect (Pharmacodynamic Enhancement): With HMG-CoA reductase inhibitors and Nicotinic acid.
Interaction-context constraints (as defined in official documents) Must be used with consideration for the binding affinity of the resin. Long-term use imposes the restriction of potential Essential Nutrient Absorption Interference.

Resulting Interaction Structure

Official Interaction Statements

  • Co-administration of Cholestyramine with other oral medicinal products is documented to result in a delay or reduction of absorption, leading to reduced serum concentration or decreased exposure of the co-administered drug.
  • Specific agents such as Warfarin, Digoxin, and Thyroid Preparations are listed as subject to this Non-Absorbable Pharmacokinetic Interference.
  • Long-term administration is officially documented to interfere with the absorption of fat-soluble vitamins (A, D, E, K) and may lead to a reduction of serum or red cell folate.
  • An official additive effect is documented when Cholestyramine is combined with HMG-CoA reductase inhibitors and Nicotinic acid, enhancing lipid-lowering outcomes.

Connection to the overall interaction profile (2–4 sentences)

The regulatory documents define the product's interaction structure primarily by its physical binding affinity as an anion-exchange resin, which results in a consistent pharmacokinetic interaction pattern of reduced absorption for numerous acidic and neutral oral drugs. This interaction mechanism mandates a strict timing separation rule for all co-administered oral medications. The profile also includes the documented requirement to monitor for Essential Nutrient Absorption Interference related to specific vitamins and folate.

Mechanism of Action

How Cholestyramine Works

Cholestyramine is a bile acid sequestrant that acts entirely within the gastrointestinal tract, modulating lipid and bile metabolism pathways. The drug is a large, non-absorbable polymer resin that remains in the small intestine, functioning as a non-systemic, peripheral binder.

Mechanistic Cascade

The drug forms an insoluble, high-affinity complex with negatively charged bile acids and bile salts, preventing their normal reabsorption by the ileum. This interaction directly interrupts the enterohepatic circulation, resulting in the excretion of bile acids in the feces. The subsequent depletion of the bile acid pool in the liver triggers a compensatory upregulation of the pathway that converts stored cholesterol into new bile acids. This metabolic demand increases the expression of LDL receptors on the hepatocyte surface, resulting in enhanced removal of LDL cholesterol from plasma. Additionally, the sequestration process facilitates the creation of a concentration gradient that lowers the level of certain circulating bile-related substances in the plasma.

Dosage and Administration Information

How to Use Cholestyramine

Cholestyramine is administered orally and is consistently supplied as a powder for oral suspension, with each standard unit dose containing 4 grams of anhydrous cholestyramine resin. The usage protocol is defined by specific preparation and timing requirements to ensure proper function and minimize administration issues.

Dosing and Administration Protocol

The most critical instruction is the mandatory requirement for dilution: the powder must never be taken in its dry form due to the risk of esophageal or airway obstruction. Each dose must be mixed thoroughly with approximately 60 to 180 mL (2 to 6 ounces) of water or another non-carbonated liquid, such as fruit juice, and consumed only after a uniform suspension is achieved.

Usage follows a flexible, divided schedule, with doses typically administered at mealtimes or before meals. The standard adult starting dose is 4 grams once or twice daily, which may be gradually increased based on the therapeutic need to a maintenance range of 8 to 16 grams daily, taken in one to six divided doses. The maximum prescribed intake is 24 grams per day.

Procedural Constraints

The binding action of cholestyramine necessitates strict time separation from other medications. To prevent interference with absorption, other oral drugs must be taken at least 1 hour before or 4 to 6 hours after cholestyramine administration. Dosage adjustments are specified for certain populations; for instance, pediatric dosing for children aged 6 to 12 is calculated based on body weight, with a limit that typically should not exceed 8 grams per day.

Recent Clinical Evidence

Cholestyramine: Recent Clinical Evidence

Cholestyramine is a bile acid sequestrant, a class of medication that binds bile acids in the intestine to prevent their reabsorption into the bloodstream. This disruption of the enterohepatic circulation promotes the conversion of cholesterol into new bile acids in the liver, which may reduce serum levels of low-density lipoprotein (LDL) cholesterol.


Established Efficacy in Lipid Management

Major long-term trials have evaluated the effect of cholestyramine on lipid levels. One notable clinical trial reported that the cholestyramine group experienced a reduction in the risk of the primary endpoint (definite coronary heart disease death and/or definite non-fatal myocardial infarction) compared to a control group. Furthermore, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were also reported to be lower in the cholestyramine group. Its use is generally considered an adjunctive therapy to diet, or for patients who may not tolerate other classes of lipid-lowering drugs.


Broader Research Areas

Beyond cholesterol reduction, clinical research continues to investigate other applications related to its bile-acid binding properties:

  • Pruritus (Itching): Cholestyramine is commonly used to manage severe itching associated with certain liver diseases, such as cholestasis, where the accumulation of bile salts is thought to contribute to the symptom.
  • Bile Acid Diarrhea: Studies have supported its role in managing chronic diarrhea resulting from bile acid malabsorption, often seen in conditions like Crohn’s disease or after ileal resection.
  • Emerging Research: Ongoing trials are exploring its potential use in accelerating the elimination of certain non-absorbed substances from the body, such as persistent organic pollutants (POPs) in specific patient populations, and in managing certain types of chronic diarrhea not linked to cholesterol.

Frequently Asked Questions (FAQ)

Common questions about Cholestyramine (FAQ)

Q: What should I do if I miss a scheduled time to take Cholestyramine?

Official product information states that if a person misses a dose, the guidance is to take it as soon as the dose is remembered. However, if the time is near the next scheduled intake, the recommendation is to skip the missed dose and continue with the regular schedule. Regulatory advice indicates that double doses are not to be taken to compensate for a missed dose.


Q: How long does it usually take to see a change in cholesterol levels with Cholestyramine?

Changes in lipid levels are typically monitored by healthcare providers through regular blood tests. Official guidance for dose adjustments specifies that lipid levels should be assessed at regular intervals, often not less than four weeks, to document the therapeutic effect.


Q: Can Cholestyramine interact with common over-the-counter pain relievers?

Regulatory documents indicate that Cholestyramine, functioning as a binder, may delay or reduce the absorption of other oral medicines when taken concurrently. This documented interaction includes certain drug categories such as non-steroidal anti-inflammatory drugs (NSAIDs).


Q: Does Cholestyramine require blood tests to monitor its effect?

According to official product labeling, monitoring of blood values is a standard component of therapy. This generally involves determining serum cholesterol and triglyceride concentrations prior to initiation and regularly (for example, every three to six months) during the course of treatment.


Q: Can taking Cholestyramine affect sleep patterns?

Sleepiness has been documented as a possible symptom related to the adverse reaction known as hyperchloremic acidosis. This is noted as a risk with prolonged use, particularly in certain patient populations, but is not listed as a common or primary side effect impacting general sleep patterns.


Q: Can Cholestyramine be taken with supplements, like fiber or herbal remedies?

Regulatory information notes that the binding action of the drug can interfere with the absorption of essential nutrients such as fat-soluble vitamins and certain oral supplements, like phosphate supplements. The need for timed separation from the medicine is documented to prevent reduced effectiveness of the co-administered products.


Q: Are there any known side effects that affect the skin or cause rashes?

Yes, while most reported side effects are concentrated in the gastrointestinal system, regulatory documents list skin irritation or rash as a possible adverse reaction. Irritation around the anus has also been reported, as have signs of an allergic reaction that may involve a rash.


Q: Can people with diabetes use Cholestyramine?

Official documents do not list diabetes mellitus as a specific contraindication or special precaution for use. However, some formulations contain ingredients, such as aspartame in sugar-free versions, whose use is restricted for individuals with the condition Phenylketonuria (PKU).


Q: Does Cholestyramine affect energy levels or cause fatigue?

Regulatory documents include both fatigue (a feeling of tiredness) and asthenia (physical weakness or lack of energy) among the less frequently reported adverse reactions associated with the use of this medicine.


Q: Are there specific symptoms that signal a need to stop taking Cholestyramine immediately?

Official guidance on severe reactions indicates that symptoms such as trouble breathing, swelling, or severe abdominal pain (which may indicate a potential intestinal obstruction) are documented as serious. These reactions should be immediately addressed by a healthcare professional.


Q: How quickly does Cholestyramine leave the system after the last dose?

Official regulatory documents indicate that the drug is non-systemic, meaning the resin is not absorbed from the digestive tract into the bloodstream. The entire compound is excreted in the feces, which means it leaves the body via the digestive system after binding bile acids.


Q: Does Cholestyramine cause weight gain or loss?

Official lists of adverse reactions report both weight loss and weight gain. These effects are listed among the rare reactions associated with the use of the medicine.


Q: Is it normal for the taste to be unpleasant, and are there flavor additives in some formulations?

Yes, some product formulations include flavor additives, such as artificial strawberry flavor, to improve palatability. Research and official documents have noted that the natural taste of the powder can present palatability issues.


Q: Is Cholestyramine the same type of medicine as statins?

No, Cholestyramine is pharmacologically classified as a bile acid sequestrant. This is a different class of medicine than statins, which are HMG-CoA reductase inhibitors. Regulatory documents note that Cholestyramine and statins may sometimes be used together for an additive, enhanced lipid-lowering effect.


Q: Do I need to follow a special diet while using Cholestyramine?

Official sources state that a standard lipid-lowering diet is recommended for patients prior to starting Cholestyramine. The recommendation is to maintain this diet throughout the course of treatment with the medication.


Q: Are there any specific foods or drinks that should be avoided when taking Cholestyramine?

Regarding preparation, the restriction is to avoid mixing the powder with carbonated beverages. This is documented to cause excessive foaming, which can make preparation and administration challenging.


Q: How does Cholestyramine impact liver function?

Official regulatory sources note that liver function abnormalities have been reported as changes observed in laboratory test results associated with the use of this medicine.


Q: Does the powder dissolve completely, or should I expect some grittiness?

The active ingredient, cholestyramine resin, is documented as being insoluble in water. When mixed with liquid, it forms a suspension, which means the powder does not fully dissolve into a clear solution.


Q: Have there been long-term studies on the safety of using Cholestyramine?

Yes, major clinical trials have evaluated the drug's effects over prolonged periods, including one notable study that lasted seven years. Official labeling also documents that prolonged use imposes a risk of fat-soluble vitamin deficiency, requiring specific monitoring.


Q: Can this medication be used long-term?

Yes, the medicine has been evaluated in long-term clinical studies. Its use for a prolonged period is documented in official labeling, which details the associated need for monitoring of essential nutrients like fat-soluble vitamins.


Q: Is it described as a first-line treatment for high cholesterol?

Official prescribing information describes the medicine's use as an adjunctive therapy (an addition) to diet for patients with elevated cholesterol. It is indicated for use when diet alone is insufficient to meet therapeutic goals.


Q: Is the primary action of the drug described as irreversible binding in the intestines?

Official documents describe the action as forming an insoluble complex with bile acids that is then excreted in the feces, preventing reabsorption. This mechanism results in the elimination of bile acids from the body via the gut.


Q: Can Cholestyramine affect the results of routine lab tests?

Yes, the medicine's use may impact the results of laboratory tests. Regulatory guidance requires regular monitoring of serum cholesterol and triglyceride concentrations. Official sources also report lab test changes such as prolonged prothrombin time and liver function abnormalities.

How should Cholestyramine be stored and disposed of?

How to Store and Dispose of Cholestyramine

Official regulatory labeling dictates strict rules for the storage and disposal of cholestyramine powder for oral suspension.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the container tightly closed and in a dry place to protect the powder from moisture.
Safety The medicine must be kept out of the reach and sight of children.

Disposal Instructions

Unused, unwanted, or expired cholestyramine must be disposed of according to local, state, and national regulations. Government guidelines strongly advise against discarding the product into household wastewater (e.g., flushing down the toilet). The preferred method for safe disposal is using a recognized medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cholestyramine found in:

A-Z Index: